scholarly journals Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

2017 ◽  
Vol 19 (7) ◽  
pp. 1024-1031 ◽  
Author(s):  
Paolo Pozzilli ◽  
Paul Norwood ◽  
Esteban Jódar ◽  
Melanie J. Davies ◽  
Tibor Ivanyi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Randomized Trial ◽  
Receptor Agonist ◽  
Daily Insulin ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

2012 ◽  
Vol 30 (1) ◽  
pp. 109-113 ◽  
Author(s):  
M. Nauck ◽  
E. Horton ◽  
M. Andjelkovic ◽  
F. J. Ampudia-Blasco ◽  
C. T. Parusel ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Randomized Trial ◽  
Open Label ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 938-P
Author(s):  
RALEIGH E. MALIK ◽  
REEMA MODY ◽  
MAUREEN J. LAGE ◽  
KRISTINA BOYE
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Timing Of Initiation ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document